UBS Group’s PhenomeX Inc. Common Stock CELL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-22,424
| Closed | -$22.4K | – | 10555 |
|
|
2023
Q3 | $22.4K | Buy |
22,424
+20,808
| +1,288% | +$15.9K | ﹤0.01% | 6746 |
|
|
2023
Q2 | $792 | Sell |
1,616
-21,603
| -93% | -$17.7K | ﹤0.01% | 8096 |
|
|
2023
Q1 | $26.9K | Buy |
23,219
+438
| +2% | +$801 | ﹤0.01% | 6870 |
|
|
2022
Q4 | $61.1K | Buy |
22,781
+18,567
| +441% | +$48.9K | ﹤0.01% | 6572 |
|
|
2022
Q3 | $12K | Buy |
4,214
+99
| +2% | +$421 | ﹤0.01% | 8229 |
|
|
2022
Q2 | $20K | Buy |
4,115
+482
| +13% | +$2.52K | ﹤0.01% | 6902 |
|
|
2022
Q1 | $26K | Sell |
3,633
-5,056
| -58% | -$41.8K | ﹤0.01% | 7163 |
|
|
2021
Q4 | $159K | Buy |
8,689
+4,437
| +104% | +$95.8K | ﹤0.01% | 5890 |
|
|
2021
Q3 | $83K | Sell |
4,252
-534
| -11% | -$20.3K | ﹤0.01% | 5959 |
|
|
2021
Q2 | $214K | Sell |
4,786
-17,980
| -79% | -$833K | ﹤0.01% | 5295 |
|
|
2021
Q1 | $1.14M | Buy |
22,766
+19,715
| +646% | +$1.34M | ﹤0.01% | 4111 |
|
|
2020
Q4 | $272K | Buy |
3,051
+1,973
| +183% | +$166K | ﹤0.01% | 5036 |
|
|
2020
Q3 | $82K | Buy |
+1,078
| New | +$68.5K | ﹤0.01% | 5297 |
|
UBS Group's CELL Position: Q4 2023 in Review
UBS Group sold out of PhenomeX Inc. Common Stock (CELL) in Q4 2023, closing a stake of 22,424 shares — an estimated $22.4K sold.
UBS Group first reported a position in CELL in Q3 2020 and held it in 13 quarters. The position peaked at $1.14M in Q1 2021. 0 funds tracked by Wall St. Rank hold CELL as of Q4 2023.
- UBS Group reported no remaining PhenomeX Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- UBS Group sold 22,424 PhenomeX Inc. Common Stock shares in Q4 2023, an estimated $22.4K.
- UBS Group first reported a position in PhenomeX Inc. Common Stock in Q3 2020 and held it in 13 quarters.
- UBS Group's PhenomeX Inc. Common Stock position peaked at $1.14M in Q1 2021.
- 0 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q4 2023.
Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.